Research programme: neurogenesis therapeutics - Newron Sweden

Drug Profile

Research programme: neurogenesis therapeutics - Newron Sweden

Alternative Names: sNN 0126; sNN 0465

Latest Information Update: 13 Sep 2013

Price : $50

At a glance

  • Originator NeuroNova AB
  • Developer Newron Sweden AB
  • Class Nerve growth factors; Peptides; Proteins; Small molecules
  • Mechanism of Action Neuron stimulants; Neuropilin-1 inhibitors; Platelet-derived growth factor receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Major depressive disorder; Neurological disorders; Parkinson's disease

Most Recent Events

  • 13 Sep 2013 Discontinued - Preclinical for Parkinson's disease in Sweden (Intracerebro-ventricular)
  • 13 Sep 2013 Discontinued - Preclinical for Neurological disorders in Sweden (PO)
  • 13 Sep 2013 Discontinued - Preclinical for Neurological disorders in Sweden (Intracerebro-ventricular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top